Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Sex on Viral Shedding and Symptom Severity During Acute COVID-19.

Pathogens & immunity·2026
Same author

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.

Microbiology spectrum·2026
Same author

Infectious Diseases Fellowship Curriculum: IDSA Training Program Directors Community of Practice (TPDCOP), Curricular and Educational REsources Workgroup (CREW).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Neonatal management and outcomes in the setting of disseminated coccidioidomycosis in pregnancy.

Journal of perinatology : official journal of the California Perinatal Association·2026
Same author

Association of long COVID with health-related quality-of-life outcomes.

Scientific reports·2026
Same author

Osteoarticular Coccidioidomycosis in California: A Single-Center Experience.

Open forum infectious diseases·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

Antiparasitic therapy.

Shanthi Kappagoda1, Upinder Singh, Brian G Blackburn

  • 1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305-5107, USA.

Mayo Clinic Proceedings
|June 2, 2011
PubMed
Summary
This summary is machine-generated.

This overview highlights recent advances in treating major human parasitic diseases, focusing on new therapies for protozoan and helminth infections affecting billions worldwide.

Related Experiment Videos

Last Updated: Jun 1, 2026

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

Area of Science:

  • * Infectious Diseases
  • * Tropical Medicine
  • * Global Health

Background:

  • * Parasitic diseases impact over 2 billion individuals globally.
  • * These infections cause significant illness and death, disproportionately affecting impoverished populations.
  • * Effective treatment is crucial for reducing disease burden.

Purpose of the Study:

  • * To provide an overview of current treatment strategies for major human protozoan and helminth infections.
  • * To highlight recent advancements in antiparasitic drug development and application.

Main Methods:

  • * Literature review of recent developments in antiparasitic therapies.
  • * Focus on treatment of major protozoan and helminth infections in humans.

Main Results:

  • * Expansion of artemisinin-based therapies for malaria treatment.
  • * Introduction of new drugs for soil-transmitted helminths and intestinal protozoa.
  • * Broadened use of antiparasitic drugs for Chagas disease.
  • * Application of combination therapy for leishmaniasis and human African trypanosomiasis.

Conclusions:

  • * Significant progress has been made in antiparasitic therapies.
  • * New treatment options offer improved management for widespread parasitic infections.
  • * Continued research and development are vital for combating global parasitic diseases.